Clinical use of serum and urine bone markers in the management of osteoporosis

References

• National Osteoporosis Foundation. Osteoporosis: review of the evidence for prevention, diagnosis, and treatment and cost effective analysis. Osteoporosis Int 1998;8:S1–S88
   Web of Science ®Google Scholar
• NIH Consensus Development Panel on Osteoporosis. J Am Med Assoc 2001:285;785–95
   PubMed Web of Science ®Google Scholar
• Consensus Development Conference. Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;94:646–50
   PubMed Web of Science ®Google Scholar
• WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group. WHO Technical Report Series 843, Geneva, Switzerland: World Health Organization; 1994. p. 1–129
   Google Scholar
• Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures [The Study of Osteoporotic Fractures Research Group]. Lancet 1993;341:72–5
   PubMed Web of Science ®Google Scholar
• Burr DB. Introduction – bone turnover and fracture risk. J Musculoskeletal Neuron Interact 2003;3(4):408–9
   PubMedGoogle Scholar
• Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;112:281–9
   PubMed Web of Science ®Google Scholar
• Sarkar S, Mitlak BH, Wong M, Stock J, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002;17:1–10
   PubMed Web of Science ®Google Scholar
• Heaney RP. Is the paradigm shifting? Bone 2003;3(4):457–65
   Google Scholar
• Riggs BL, Melton III LJ. Bone turnover matters: the raloxifene treatment paradox of dramatic decrease in vertebral fractures without commensurate increase in bone density. J Bone Miner Res 2002;17:11–4
   PubMed Web of Science ®Google Scholar
• Melton LJ, Khosla S, Atkinson EJ, O’Fallon WO, Riggs BL. Relationship of bone turnover to bone density and fractures. J Bone Miner Res 1997;12:1083–91
   PubMed Web of Science ®Google Scholar
• Dempster DW. The impact of bone turnover and bone-active agents on bone quality: focus on hip. Osteoporosis Int 2002;13:349–52
   PubMed Web of Science ®Google Scholar
• Sarkar S, Reginster J, Crans GG, Diez-Perez A, Pinette Karen V, Delmas PD. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 2004;19(3):394–401
   Google Scholar
• Bauer, DC, Black DM, Garnero, P, et al., for the Fracture Intervention Trial Study Group. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004;19(8):1250–8
   Google Scholar
• Parfitt AM. High bone turnover is intrinsically harmful: two paths to a similar conclusion. The Parfitt view. J Bone Miner Res 2002;17(8):1558–9 [discussion 1560]
   Google Scholar
• Miller PD, Baran DT, Bilezekian J, et al. Practical clinical applications of biochemical markers of bone turnover. J Clin Densitometry 1999;2(3):323–42
   PubMed Web of Science ®Google Scholar
• Agerbaek MO, Eriksen EF, Kragstrup J, Mosekilde L, Melsen F. A reconstruction of the remodeling cycle in normal human cortical iliac bone. Bone Miner 1991;12(2):101–12
   Google Scholar
• Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000;21:115–37
   PubMed Web of Science ®Google Scholar
• Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7(11):1251–8
   PubMed Web of Science ®Google Scholar
• Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994;40(11):2022–5
   Google Scholar
• Bettica P, Taylor AK, Talbot J, Talamani R, Baylink DJ. Clinical performance of galactosyl hydroxylysine, pyridinoline, and deoxypyridinoline in postmenopausal osteoporosis. J Clin Endocrinol Metab 1996;81:542–6
   PubMed Web of Science ®Google Scholar
• Boivin G, Meunier PJ. The degree of mineralization of bone tissue measured by computerized quantitative contact microradiography. Calcif Tissue Int 2002;70(6):3–11
   Google Scholar
• Einhorn TA. Bone strength: the bottom line. Calcif Tissue Int 51;1992:333–9
   PubMed Web of Science ®Google Scholar
• Parfitt AM. Use of bisphosphonates in the prevention of bone loss and fractures. Am J Med 1991;91(5B):42S–46S
   Google Scholar
• Oleksik A, Ott SM, Vedi S, Bravenboer N, Compston J, Lips P. Bone structure in patients with low bone mineral density with or without vertebral fractures. J Bone Miner Res 2000;15(7): 1368–75
   PubMed Web of Science ®Google Scholar
• Legrand E, Chappard D, Pascaretti C, et al. Trabecular bone microarchitecture, bone mineral density, and vertebral fractures in male osteoporosis. J Bone Miner Res 2000;15(1):13–9
   PubMed Web of Science ®Google Scholar
• Chestnut CH, Clark GS, English SC, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type-I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997;102:29–37
   PubMed Web of Science ®Google Scholar
• Ross PD, Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res 1998;13(2):297–302
   PubMed Web of Science ®Google Scholar
• Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res 1999;14(9): 1614–21
   PubMed Web of Science ®Google Scholar
• Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996;11(10):1531–8
   PubMed Web of Science ®Google Scholar
• Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial [FIT Research Group]. J Clin Endocrinol Metab 2000;85(11):4118–24
   PubMed Web of Science ®Google Scholar
• Reginster JY, Minne HW, Sorenson OH, et al. Randomized trial of the effects of residronate on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial [Vertebral Efficacy With Residronate Therapy (VERT) Study Group]. J Am Med Assoc 1999;282(14): 1344–52
   Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. J Am Med Assoc 1999;282:637–45
   PubMed Web of Science ®Google Scholar
• Chesnut 3rd CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study [PROOF Study Group]. Am J Med 2000;109(4):267–76
   Google Scholar
• Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18(6):1051–6
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of non-vertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002;87(4):1586–92
   PubMed Web of Science ®Google Scholar
• Dobing H, Fahrleitner A, Ste-Marie L, et al. Early changes in biochemical markers of bone formation predict improvements in bone structure during teriparatide therapy. 85th Annual Meeting of The Endocrine Society, Program & Abstracts, 2003. p. 131
   Google Scholar
• Braga de Castro-Machado A, Hannon R, Eastell R. Monitoring alendronate therapy for osteoporosis. J Bone Miner Res 1999;14(4):602–8
   Google Scholar
• Raisz L, Smith JA, Trahiotis M, et al. Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover. Osteoporos Int 2000;11(7):615–20
   PubMed Web of Science ®Google Scholar
• Medicare program; negotiated rulemaking: coverage and administrative policies for clinical diagnostic laboratory services; final rule. November 23, 2001, [66 FR 58843–58846]
   Google Scholar
• Garnero P, Mulleman D, Munoz F, Sornay-Rendu E, Delmas PD. Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study. J Bone Miner Res 2003;18(10):1789–94
   Google Scholar
• Lane NE, Sanchez S, Genant HK, Jenkins DK, Arnaud CD. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporosis Int 2000;11(5):434–42
   Google Scholar
• Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM. Intermittently administered human parathyroid hormone (1–34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 2001;16(1):157–65
   PubMed Web of Science ®Google Scholar
• Akesson K, Ljunghall S, Jonsson B, et al. Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: a retrospective and prospective population-based study of women. J Bone Miner Res 1995;10(11):1823–9
   PubMed Web of Science ®Google Scholar
• Ravaud P, Reny JL, Giraudeau B, Porcher R, Dougados M, Roux C. Individual smallest detectable difference in bone mineral density measurements. J Bone Miner Res 1999;4(8):1449–56
   Google Scholar
• Trovas GP, Lyritis GP, Galanos A, Raptou P, Constantelou EA. Randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res 2002;17(3):521–7
   Google Scholar
• Srivastava AK, Libanati C, Hohmann O, Kriegman A, J Baylink DJ. Effects of calcitonin nasal spray on serum C-telopeptide levels in elderly osteopenic women with increased bone turnover. Calcif Tissue Int 2004;75:477–81
   Google Scholar
• Haynes RB, Montague P, Oliver T, McKibbon KA, Brouwers MC, Kanani R. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev CD000011, 2000
   Google Scholar
• Turbi C, Herrero-Beaumont G, Acebes JC, et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 2004;26(2):245–56
   PubMed Web of Science ®Google Scholar
• Davies GC, Huster WJ, Lu Y, Plouffe Jr L, Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999;93:558–65
   Google Scholar
• Recker RR, Gallagher R, Amonkar M, Smith JC, MacCosbe PE. Medication persistence is better with weekly bisphosphonates, but it remains suboptimal. Poster SA407, presented at: 26th Annual Meeting of the American Society for Bone Mineral Research, October 1–5, 2004, Seattle, WA
   Google Scholar
• Clowes JA, Peel NFA, Eastell R. The effect of monitoring on adherence and persistence with raloxifene therapy and the impact of the effectiveness of treatment. J Bone Miner Res 2002;17(Suppl 1):S155
   Google Scholar
• Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004;89(3):1117–23
   Google Scholar
• Eastell R, Garnero P, Vrijens B, et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Presented at the 30th European Symposium on Calcified Tissues, May 8–12, 2003, Rome, Italy
   Google Scholar
• Delmas PD, Vrijens B, Roux C, et al. A reinforcement message based on bone turnover marker response influences long-term persistence with risedronate in osteoporosis: the IMPACT study. J Bone Miner Res. 2003;18(Suppl 2):S374
   Google Scholar
• The Swedish Council on Technology Assessment in Health Care. Bone density measurement – a systematic review: a report from SBU. J Intern Med 1997;241\(Suppl 739):5–11,12–22,42–4
   Google Scholar
• Assessment of osteoporotic fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994;843:1–129
   PubMedGoogle Scholar
• Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement 2000;17(1):1–36
   Google Scholar
• Physician’s Guide to Prevention and Treatment of Osteoporosis. 2nd ed. Washington, DC: National Osteoporosis Foundation; 2003. Position statement: executive summary
   Google Scholar
• Unites States Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med 2002;137(6):526–8. Source description. Available from www.ahrq.gov/clinic/epcsums/osteosum.htm
   Google Scholar
• The Writing Group for the International Society for Clinical Densitometry (ISCD) Position Development Conference. J Clin Densitom. 2004;7:7–12
   PubMedGoogle Scholar
• Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001;286(22):2815–22
   Google Scholar
• Hannon R, Blumsohn A, Naylor K, Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 1998;13(7):1124–33
   PubMed Web of Science ®Google Scholar
• Eastell R, Mallinak N, Weiss S, Ettinger M, Pettinger M, Cain D, et al. Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res 2000;15(3):594–8
   PubMed Web of Science ®Google Scholar
• Hannon R, Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporosis Int 2000;11 Suppl 6: S30–44
   PubMedGoogle Scholar
• Vesper HW, Demers LM, Eastell R, Garnero P, Kleerekoper M, Robins SP, et al. Assessment and recommendations on factors contributing to preanalytical variability of urinary pyridinoline and deoxypyridinoline. Clin Chem 2002;48(2):220–35
   PubMed Web of Science ®Google Scholar
• Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone. 2002:31(1);57–61
   Google Scholar
• South-Paul JE. Osteoporosis Part I. Evaluation and Assessment. Am Family Phy 2001:63(5);897–904
   Google Scholar
• Nishizawa Y, Nakamura T, Ohata H, et al. Guidelines on the use of biochemical markers of bone turnover in osteoporosis (2001). J Bone & Miner Metabolism 2001;19:338–44
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:143–41
   Google Scholar